David Walsey
Investor Relations Contact at MEI PHARMA, INC.
Profile
David A.
Walsey is currently working as the SVP-Corporate Affairs & VP-Investor Relations at MEI Pharma, Inc. He previously worked as the Senior Director-Investor Relations at Sarepta Therapeutics, Inc. From 2005 to 2009, he held the position of Director-Corporate Communications at Arena Pharmaceuticals, Inc. He also served as the Head-Investor Relations & Corporate Communications at Maxim Pharmaceuticals, Inc. and as the VP-Investor Relations & Corporate Communications at Optimer Pharmaceuticals LLC.
Additionally, he worked as the Vice President-Corporate Communications at Lundbeck Seattle BioPharmaceuticals, Inc. Mr. Walsey completed his undergraduate degree at Franklin & Marshall College and his graduate degrees at Brooklyn Law School and New York University School of Law.
David Walsey active positions
| Companies | Position | Start |
|---|---|---|
| MEI PHARMA, INC. | Investor Relations Contact | 31/01/2018 |
Former positions of David Walsey
| Companies | Position | End |
|---|---|---|
| ARENA PHARMACEUTICALS | Public Communications Contact | 31/12/2008 |
| Maxim Pharmaceuticals, Inc. | Public Communications Contact | - |
| ALDER BIOPHARMACEUTICALS, INC. | Investor Relations Contact | - |
| SAREPTA THERAPEUTICS, INC. | Public Communications Contact | - |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Investor Relations Contact | - |
Training of David Walsey
| New York University School of Law | Graduate Degree |
| Brooklyn Law School | Graduate Degree |
| Franklin & Marshall College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
| Maxim Pharmaceuticals, Inc. | Health Technology |
- Stock Market
- Insiders
- David Walsey
